drugset / Trial / NCT06437678
Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the objective response rate (ORR) and disease control rate (DCR) of liposomal irinotecan monotherapy in the treatment of recurrent/refractory advanced gastric cancer.
Timeline
- Start
- 2024-05-27
- Primary completion
- 2025-02-28
- Completion
- 2026-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 56.5 mg/m2 | — |